Table 1.
Demographics of participants
| ROSZ | UHR | HC | Statistics | |
|---|---|---|---|---|
| N (sex ratio M/F)a | 21 (11/10) | 27 (14/13) | 24 (10/14) | χ2 = 0.696, df = 2, p = 0.706 |
| Age (years)b | 24.0 (6.7) | 20.6 (3.9) | 22.3 (3.0) | F2,69 = 3.04, p = 0.054 |
| Education (year)b | 13.4 (2.5) | 13.1 (2.6) | 14.5 (1.6) | F2,69 = 2.29, p = 0.109 |
| Premorbid IQb | 104 (9.0) | 105 (8.1) | 110 (6.4) | F2,69 = 3.03, p = 0.055 |
| DOI (weeks) | 46.5 (47.0) | |||
| PANSSc total | 68.9 (19.6) | 67.7 (14.3) | t46 = 0.238, p = 0.813 | |
| Positive | 15.2 (5.3) | 14.3 (3.7) | t46 = 0.684, p = 0.497 | |
| Negative | 18.8 (7.0) | 17.3 (4.7) | t46 = 0.874, p = 0.387 | |
| General | 34.9 (10.0) | 36.1 (8.0) | t46 = –0.466, p = 0.643 | |
| GAF scorec | 38 (11) | 48 (10) | t46 = –3.35, p = 0.002 | |
| Antipsychotic dose (mg/day)c | 388 (284) | 174 (262) | t46 = 2.70, p = 0.010 |
All values are shown as mean (standard deviation) except for the first row. Underlined results indicate p < 0.05
ROSZ recent-onset schizophrenia, UHR ultra-high risk, HC healthy control, IQ intelligence quotient, DOI duration of illness, PANSS positive and negative symptom scale, GAF global assessment of functioning, ANOVA analysis of variance, df degrees of freedom
aChi-square test
bOne-way ANOVA
cIndependent t-test